Research & Academics

Research & Academics

Share this:


Video: Sideny Mallenbaum, M.D. discusses the current clinical trial being conducted for stroke patients.

REDUCE: PFO Closure Study

GORE® HELIX® Septal Occluder/GORE® Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patient Foramen Ovale (PFO): REDUCE

Protocol Description

The primary objective is to determine that patent foramen ovale (PFO) closure with the GORE® HELEX® Septal Occluder / GORE® Septal Occluder plus antiplatelet medical management is safe and effective and reduces the risk of recurrent stroke or imaging-confirmed transient ischemic attack (TIA) when compared to antiplatelet medical management alone in patients with a PFO and history of cryptogenic stroke.